Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units
Familial Cancer · 22.05.2026 · 25 (2)
DOI: 10.1007/s10689-026-00571-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Familial Cancer, online erschienen am 22.05.2026. Verfasst von Beatriz Grau Mirete und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain. beagrau96@gmail.com. Hauptthemen laut MEDLINE: Germ-Line Mutation, Li-Fraumeni Syndrome, Tumor Suppressor Protein p53. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Germline TP53 pathogenic or likely pathogenic variants underlie Li-Fraumeni syndrome (LFS), but with broader use of multigene panel (MGP) testing, carriers are increasingly identified outside classic criteria. We retrospectively studied 36 carriers from 18 families evaluated at two Spanish hereditary cancer units (2005-2023). Clinical data were obtained from medical records, and variants were functionally classified using the Giacomelli model and IARC thresholds as dominant-negative with loss of function (DNE_LOF), non-dominant-negative without loss of function (noDNE_noLOF), non-dominant-negative with loss of function, or not assessed. Descriptive statistics summarized the tumor spectrum and group comparisons were performed using the Mann-Whitney U test (α = 0.05). Overall, 23 of 36 carriers (63.9%) developed at least one malignancy; 58.3% were female and the median age at first cancer was 36 years (range 27-54). Patients identified through MGP testing had later onset compared with those meeting clinical LFS criteria (median 42 [37-58] versus 27 [4-30] years; p = 0.011). Breast cancer was the most frequent tumor (65% of first cancers, median age 37 [30-47]), whereas none of the MGP-ascertained carriers developed LFS "core" tumors (sarcoma, brain tumor, adrenocortical carcinoma). Fifteen distinct germline variants were identified; 80% were missense, mainly in exons 5-8. DNE_LOF (median 30 [25-38.5]) were associated with earlier onset compared with noDNE_noLOF (47 [37-63]; p = 0.034). Eight carriers (34.7%) developed second primaries after a median interval of 6 years, and four developed third primaries. Functional classification may contribute to risk stratification; however, these findings are exploratory and hypothesis-generating, and require validation in larger prospective cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain. beagrau96@gmail.com.
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain.
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Zitieren
APA
Mirete, B. G., Arias, A. F., Payá, P. R., Revert, M. V., Garcia, D. S., Marín, M. M., Benítez-Fuentes, J. D., González, I. C., & Heras, A. B. S. (2026). Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units. Familial Cancer, 25(2). https://doi.org/10.1007/s10689-026-00571-2
Vancouver
Mirete BG, Arias AF, Payá PR, Revert MV, Garcia DS, Marín MM, et al. Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units. Familial Cancer. 2026;25(2). doi:10.1007/s10689-026-00571-2
BibTeX
@article{Mirete2026,
author = {Mirete, Beatriz Grau and Arias, Asia Ferrández and Payá, Paula Rodríguez and Revert, María Valero and Garcia, David Sánchez and Marín, Mariano Martínez and Benítez-Fuentes, Javier-David and González, Isabel Chirivella and Heras, Ana Beatriz Sánchez},
title = {Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units},
journal = {Familial Cancer},
year = {2026},
volume = {25},
number = {2},
doi = {10.1007/s10689-026-00571-2}
}
EUVIMED